Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Age at onset in genetic prion disease and the design of preventive clinical trials.

Minikel EV, Vallabh SM, Orseth MC, Brandel JP, Haïk S, Laplanche JL, Zerr I, Parchi P, Capellari S, Safar J, Kenny J, Fong JC, Takada LT, Ponto C, Hermann P, Knipper T, Stehmann C, Kitamoto T, Ae R, Hamaguchi T, Sanjo N, Tsukamoto T, Mizusawa H, Collins SJ, Chiesa R, Roiter I, de Pedro-Cuesta J, Calero M, Geschwind MD, Yamada M, Nakamura Y, Mead S.

Neurology. 2019 Jul 9;93(2):e125-e134. doi: 10.1212/WNL.0000000000007745. Epub 2019 Jun 6.

PMID:
31171647
2.

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD.

Ermann N, Lewczuk P, Schmitz M, Lange P, Knipper T, Goebel S, Kornhuber J, Zerr I, Llorens F.

Ann Clin Transl Neurol. 2018 May 26;5(7):883-887. doi: 10.1002/acn3.584. eCollection 2018 Jul.

3.

Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance.

Hermann P, Laux M, Glatzel M, Matschke J, Knipper T, Goebel S, Treig J, Schulz-Schaeffer W, Cramm M, Schmitz M, Zerr I.

Neurology. 2018 Jul 24;91(4):e331-e338. doi: 10.1212/WNL.0000000000005860. Epub 2018 Jun 22.

PMID:
29934424
4.

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases.

Zerr I, Schmitz M, Karch A, Villar-Piqué A, Kanata E, Golanska E, Díaz-Lucena D, Karsanidou A, Hermann P, Knipper T, Goebel S, Varges D, Sklaviadis T, Sikorska B, Liberski PP, Santana I, Ferrer I, Zetterberg H, Blennow K, Calero O, Calero M, Ladogana A, Sánchez-Valle R, Baldeiras I, Llorens F.

Alzheimers Dement. 2018 Jun;14(6):751-763. doi: 10.1016/j.jalz.2017.12.008. Epub 2018 Feb 3.

PMID:
29391125
5.

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia.

Llorens F, Schmitz M, Knipper T, Schmidt C, Lange P, Fischer A, Hermann P, Zerr I.

Front Aging Neurosci. 2017 Sep 12;9:289. doi: 10.3389/fnagi.2017.00289. eCollection 2017.

6.

Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.

Llorens F, Kruse N, Karch A, Schmitz M, Zafar S, Gotzmann N, Sun T, Köchy S, Knipper T, Cramm M, Golanska E, Sikorska B, Liberski PP, Sánchez-Valle R, Fischer A, Mollenhauer B, Zerr I.

Mol Neurobiol. 2018 Mar;55(3):2249-2257. doi: 10.1007/s12035-017-0479-5. Epub 2017 Mar 21.

7.

Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.

Llorens F, Kruse N, Schmitz M, Gotzmann N, Golanska E, Thüne K, Zejneli O, Kanata E, Knipper T, Cramm M, Lange P, Zafar S, Sikorska B, Liberski PP, Mitrova E, Varges D, Schmidt C, Sklaviadis T, Mollenhauer B, Zerr I.

Alzheimers Dement. 2017 Jun;13(6):710-719. doi: 10.1016/j.jalz.2016.09.013. Epub 2016 Nov 18.

PMID:
27870938

Supplemental Content

Loading ...
Support Center